Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis

NCT07101055 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

End-Stage Kidney Disease (ESKD)

Interventions

DRUG: Letermovir 480 mg [PREVYMIS]

Sponsor

Jason A Roberts

Collaborators

[object Object]
[object Object]